Investor Presentaiton
iber/mezi
Hematology
Reblozyl BET Inhibitor Breyanzi
golcadomide Abecma
alnuctamab
GPRC5D
Phase 3 INDEPENDENCE 1L TD anemia in MF trial design1
Key Eligibility Criteria:
MPN-associated MF
• Stable dose JAK2 inhibitor
• Transfusion dependent
Stratification:
Blinded Core
Treatment Period
(24 weeks)
Extended
Treatment
(Week 25+)
Luspatercept + JAK2i
SQ every 3 weeks
•
BL RBC transfusion burden
R
DIPSS (intermediate vs. high)
2:1
Primary Endpoint:
•
RBC transfusion independence
Placebo + JAK2i
SQ every 3 weeks
Day 169 Response
Assessment:
RBC-TI 12W/24W
Continued Treatment
Crossover from placebo to
lusptercept allowed if no
response at primary
endpoint response
assessment
for ≥12 weeks
Key Secondary Endpoint:
RBC transfusion independence
for ≥16 weeks
Ill Bristol Myers Squibb™ 1. NCT04717414
Expected data readout 2025
Not for Product Promotional Use
76View entire presentation